Menu
Recruiting NCT06291116

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

Phase II Interventional Kidney Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: standard care + rotigotine at 4 mg/24h for 24 months., standard care for 24 months..
Who it may be relevant to
Registry conditions: Kidney Diseases. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is caused by mutations in the PKD1 or PKD2 genes, which encode polycystins 1 and 2. Patients develop renal cysts associated with a progressive decline in kidney function, ultimately leading to end-stage renal disease in approximately one third of cases. ADPKD is also characterized by early-onset hypertension and cardiovascular complications, notably intracranial aneurysms. This phenotype is related to abnormal polycystin function in the primary cilia of renal epithelial and vascular endothelial cells, resulting in impaired mechanotransduction of shear stress induced by urinary and blood flow and subsequent alterations in multiple cellular functions. Experimental studies have suggested that stimulation of dopamine receptor type 5 (DR5) may restore endothelial mechanosensitivity. This hypothesis is supported by our preliminary results showing that local administration of dopamine improves endothelial function in patients with ADPKD through restoration of nitric oxide (NO) release in response to increased blood flow. Consistent with these findings, the IMPROVE-PKD study recently demonstrated similar beneficial effects on endothelial function and hemodynamics using rotigotine, a dopamine agonist administered via transdermal patches for two months at a low dose (4 mg/24 h). Dopaminergic stimulation may also prevent renal abnormalities related to polycystin deficiency. We therefore hypothesize that rotigotine could slow the progression of ADPKD at both the renal and cardiovascular levels. This phase 2 study aims to evaluate the long-term tolerability of rotigotine in patients with ADPKD and to collect preliminary data on its effects on renal outcomes.

Interventions

  • Drug standard care + rotigotine at 4 mg/24h for 24 months.
    standard care + rotigotine at 4 mg/24h for 24 months.
  • Drug standard care for 24 months.
    standard care for 24 months.

Primary outcome measures

  • Evaluate the safety and tolerability of rotigotine administered at a dose of 4 mg/24h for 24 months in patients with ADPKD [Time frame: throught 24 months]

Eligibility criteria

Inclusion criteria

  • ADPKD patients aged 18 to 60 years
  • Normotensive or hypertensive patients treated controlled (SBP/DBP on daytime ABPM <135/85 mmHg less than 3 months old)
  • Patient having read and understood the information letter and signed the consent form
  • Effective contraception in women of childbearing age (for postmenopausal women, a confirmatory diagnosis should be obtained)
  • Patient benefiting from a social protection scheme

Exclusion criteria

  • Stage 4 or 5 renal insufficiency (GFR CKD-EPI <30 ml/min)
  • Renal transplant patients
  • Dialysis patients
  • History of myocardial infarction or stroke less than 6 months old
  • Severe hepatic insufficiency (Child-Pugh class C)
  • Patients currently being treated or treated in the 6 months preceding the trial with a dopamine agonist or antagonist
  • Systolic heart failure requiring hospitalization in the 6 months preceding inclusion or known heart failure with an LVEF <30%
  • Orthostatic hypotension (decrease > 20 mm Hg)
  • Pregnant, breastfeeding woman, or proven absence of contraception
  • Excessive alcohol consumption (greater than 20 g/day)
  • History of addictive behavior, particularly gambling, compulsive purchasing or hypersexuality
  • Drug addiction or suspected illicit drug use
  • Taking other sedative medications or other central nervous system depressants (benzodiazepines, antipsychotics, antidepressants or neuroleptics with antiemetic intent)
  • Hypersensitivity to the active ingredient, rotigotine, or to one of its excipients
  • Known allergy to sulphites
  • Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection, or guardianship or curatorship.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

France · 4 centers
  • CHU d'AMIENS — Amiens
  • CHRU de CAEN — Caen
  • CHU de LILLE — Lille
  • CHU de ROUEN — Rouen

Publications

  • St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3. PMID 39356039

Identifiers

NCT: NCT06291116 · 2022/0345/HP

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗